Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued to investors on Thursday. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a report on Friday, November 15th.

Aethlon Medical Trading Up 3.1 %

AEMD opened at $0.61 on Thursday. The company has a market cap of $8.46 million, a price-to-earnings ratio of -0.21 and a beta of 1.79. The stock has a fifty day simple moving average of $0.42 and a two-hundred day simple moving average of $0.43. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $2.35.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.